Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GTB 3550

Next Previous
Drug Profile

GTB 3550

Alternative Names: 161533 TriKE; cam16-IL15-camB7H3; CD16/IL-15/CD33 - Oxis Biotech; CD16/IL-15/CD33 Tri-Specific Killer Engagers (TriKes); GTB-3550; GTB-3550 TriKE™; OXIS3550; OXS-3550; OXS-3550-TriKE

Latest Information Update: 06 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Minnesota
  • Developer Oxis Biotech; University of Minnesota
  • Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoglobulin fragments; Immunotherapies; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Myelodysplastic syndromes; Non-small cell lung cancer; Systemic mastocytosis

Most Recent Events

  • 06 May 2024 Discontinued - Phase-I/II for Acute myeloid leukaemia (Second-line therapy or greater) in USA (Parenteral)
  • 06 May 2024 Discontinued - Phase-I/II for Myelodysplastic syndromes (Second-line therapy or greater) in USA (Parenteral)
  • 06 May 2024 Discontinued - Phase-I/II for Systemic mastocytosis in USA (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top